arrow
D

David E. Gerber

ut southwestern medical center
H指数:60
被引数:2.5万

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Patient reimbursement in therapeutic cancer clinical trials: An 18‐year multicenter experience

治疗性癌症临床试验中的患者报销:一项为期18年的多中心经验

Cancer
IF5.1
2026-11-090
PRE
Deciphering small sequence differences in T cell receptor-antigen pairing

解析T细胞受体-抗原配对的微小序列差异

2026-06-130
OAAI
Nivolumab plus chemoradiotherapy followed by nivolumab with or without ipilimumab for untreated locally advanced stage III NSCLC: a randomized phase 3 trial

纳武利尤单抗联合放化疗后序贯纳武利尤单抗联合或不联合伊匹木单抗治疗未经治疗的局部晚期Ⅲ期非小细胞肺癌:一项随机Ⅲ期试验

2026-05-130
OAAI
Health Beliefs and Adherence to Lung Cancer Screening in a Diverse Safety-Net Population

健康信念与多样化安全网人群中肺癌筛查的依从性

2026-01-010
PRE
Radiomics for Dynamic Lung Cancer Risk Prediction in USPSTF-Ineligible Patients

基于放射组学的动态肺癌风险预测(针对USPSTF非适用人群)

2025-10-230
OAAI
The influence of body mass index on tumor Treating Fields therapy in patients with metastatic non-small cell lung cancer: A post-hoc and simulation analysis from the phase III LUNAR study

体重指数对转移性非小细胞肺癌患者肿瘤治疗电场疗法的影响:一项来自III期LUNAR研究的回顾性及模拟分析

2025-10-210
PRE
Feasibility of Atezolizumab in Combination With Chemotherapy for Children With Relapsed or Refractory Solid Tumors

阿特珠单抗联合化疗治疗复发或难治性实体瘤患儿的可行性

2025-09-010
OAAI
Osimertinib plus consolidative radiotherapy for advanced EGFR mutant non–small cell lung cancer: a multicentre, single-arm, phase 2 trial

奥希替尼联合巩固性放疗治疗晚期EGFR突变非小细胞肺癌:一项多中心、单臂、II期临床试验

2025-08-260
PREAI
Profiling antigen-binding affinity of B cell repertoires in tumors by deep learning predicts immune-checkpoint inhibitor treatment outcomes

通过深度学习分析肿瘤中B细胞库的抗原结合亲和力,可预测免疫检查点抑制剂治疗结局

2025-06-270
PRE